Article
Medicine, General & Internal
Bangxiang Xie, Qian Hao, Xiang Zhou, Dexi Chen
Summary: The HBx protein of hepatitis B virus interacts with the TAp63 protein and inhibits its transcriptional activity, leading to the progression of hepatocellular carcinoma with defective p53.
CHINESE MEDICAL JOURNAL
(2022)
Article
Genetics & Heredity
Yang Yang, Yajuan Qu, Zhaopeng Li, Zhiyong Tan, Youming Lei, Song Bai
Summary: This study provides a detailed analysis of TP53-mutated hepatocellular carcinoma (HCC), offering new insights for individualized therapy and accurate prognosis prediction.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Alvin Kunyao Guo, Yoko Itahana, Veerabrahma Pratap Seshachalam, Hui Ying Chow, Sujoy Ghosh, Koji Itahana
Summary: This study identified a novel interaction between TP53(R273H) and BCAR1, where BCAR1 translocates from the cytoplasm to the nucleus and binds to TP53(R273H) in a manner dependent on SRC family kinases (SFKs), promoting cancer cell invasion. High BCAR1 expression was associated with a poorer prognosis among patients with mutant TP53, highlighting the potential therapeutic approach of disrupting the TP53(R273H)-BCAR1 binding in TP53(R273H)-harbouring cancer patients.
BRITISH JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Chiao-Fang Teng, Tsai-Chung Li, Ting Wang, Da-Ching Liao, Yi-Hsuan Wen, Tzu-Hua Wu, John Wang, Han-Chieh Wu, Woei-Cherng Shyu, Ih-Jen Su, Long-Bin Jeng
Summary: Hepatocellular carcinoma (HCC) is closely associated with chronic hepatitis B virus (HBV) infection. The oncoprotein pre-S2 mutant plays important roles in HCC development and is linked to poor prognosis in HCC patients. In pre-S2 mutant-positive HCC patients, there is a higher infiltration of regulatory T cells (Tregs) but a lower infiltration of cytotoxic T lymphocytes (CTLs) in tumor tissues.
SCIENTIFIC REPORTS
(2021)
Review
Virology
Arpita Kar, Abhisekh Samanta, Soumyadeep Mukherjee, Subhasis Barik, Avik Biswas
Summary: Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC), the most common primary liver malignancy. The study of HBV-host interactions has identified various mechanisms involved in the development and progression of HBV-associated HCC. This review provides a comprehensive summary of the existing knowledge on HBV-host interplay and highlights new therapeutic strategies for HBV-induced HCC.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Virology
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxi
Summary: Hepatitis B virus (HBV) infection is associated with the risk of developing hepatocellular carcinoma (HCC), with or without liver cirrhosis, through various mechanisms. The molecular profile of HBV-HCC is constantly being studied, and it is the result of altered molecular pathways, changes in the microenvironment, and DNA damage. Proper management of HBV-related liver disease is crucial for prevention and treatment of HCC.
Article
Biochemical Research Methods
Chen Yang, Xiaowen Huang, Yan Li, Junfei Chen, Yuanyuan Lv, Shixue Dai
Summary: This study retrospectively analyzed 1135 HCC patients and developed a random forest-based prediction model to estimate TP53 mutational status, as well as a robust poor prognosis-associated signature which showed superior ability to predict survival in TP53-mutant patients. In silico screening revealed three targets and two agents that might have potential therapeutic implications in high-PPS patients, presenting a comprehensive view of potential treatment strategy.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Medicine, Research & Experimental
Wensheng Deng, Jiaoyu Ai, Wanlin Zhang, Zhenyu Zhou, Muqi Li, Likun Yan, Lidong Zhang, Zongjing Huang, Ziyi Wu, Junhua Ai, Hai Jiang
Summary: The HBx/PRMT9/HSPA8/CD44 axis was identified as a key signaling pathway regulating ferroptosis in HCC cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Meng Xue, Xiaona Lin, Qiu-Xiong Lin, Xiaoyong Pu, Jiumin Liu, Xing-Fang Li, Jun Hou, Xudong Liu, Ren Chen
Summary: This study found that HBV infection was associated with an increased risk of HCC compared to HEV infection, and that HEV infection may mitigate the promoting impact of HBV on HCC development.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Chen Shen, Xin Jiang, Mei Li, Yao Luo
Summary: Hepatocellular carcinoma (HCC) is a global health challenge caused by hepatitis virus infection. Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) are major risk factors for HCC development. This review discusses the mechanisms by which these viruses induce HCC and presents new diagnostic and therapeutic approaches. The potential relationship between hepatitis E virus (HEV) and HCC is also considered.
Review
Oncology
Xinhe Zhang, Lin Guan, Haoyu Tian, Zilu Zeng, Jiayu Chen, Die Huang, Ji Sun, Jiaqi Guo, Huipeng Cui, Yiling Li
Summary: HCC is a common cancer with increasing incidence caused by HBV and HCV infections, liver cirrhosis, and metabolic risk factors. Predictive factors can assess the risk of HCC, and prevention strategies include vaccination, antiviral treatment, and HCC management to reduce recurrence.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Nicholas Noverati, Rukaiya Bashir-Hamidu, Dina Halegoua-DeMarzio, Hie-Won Hann
Summary: Hepatitis B virus is a significant cause of hepatocellular carcinoma globally. The complex mechanisms of this virus include interactions with the host's immune system. Factors such as stress can amplify these mechanisms. Chronic stress, harmful to health, can suppress or activate the host's defense system, leading to tumor initiation and progression in liver cancer. Chronic stress, often overlooked, should be recognized as a potential risk factor.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Mirjam B. Zeisel, Francesca Guerrieri, Massimo Levrero
Summary: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is largely caused by chronic hepatitis B virus (HBV) infection. While antiviral therapies can suppress viral replication, there is currently no cure for chronic HBV infection. HBV contributes to liver carcinogenesis through direct and indirect effects on host epigenetic alterations, modulating gene expression.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Virology
Patrizia Farci, Grazia Anna Niro, Fausto Zamboni, Giacomo Diaz
Summary: Hepatitis D virus (HDV) is a small RNA virus that relies on hepatitis B virus (HBV) for virion assembly and transmission, and can lead to chronic hepatitis D. Studies have shown that HDV is associated with a significantly higher risk of hepatocellular carcinoma (HCC) compared to HBV monoinfection. The mechanisms by which HDV promotes liver cancer are still unclear, but recent data suggest that HDV and HBV promote carcinogenesis through distinct molecular mechanisms.
Article
Biochemistry & Molecular Biology
Kei Takuma, Shintaro Fujihara, Koji Fujita, Hisakazu Iwama, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Joji Tani, Tingting Shi, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Tsutomu Masaki
Summary: This study investigates the antitumor mechanism of regorafenib on hepatocellular carcinoma (HCC) and the impact on microRNA (miRNA) expression. The results suggest that regorafenib inhibits cell proliferation and tumor growth in HCC by altering the cell cycle and miRNA expression, particularly downregulating cyclin D1.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pathology
B. Delahunt, A. Steigler, C. Atkinson, D. Christie, G. Duchesne, L. Egevad, D. Joseph, D. N. Kenwright, J. Matthews, J. D. Murray, C. Oldmeadow, H. Samaratunga, N. A. Spry, M. C. Thunders, H. Hondermarck, J. W. Denham
Summary: Previous reports have shown that quantifying high tumour grade in prostate cancer patients is of prognostic significance. This study found that the length, percentage, and absolute values of Gleason pattern 4 (GP4) were significantly associated with distant progression of tumour, all-cause mortality, and cancer-specific mortality over a 10-year follow-up period. In addition, these parameters outperformed the division of cases according to Gleason score in terms of prognostic significance.
Article
Endocrinology & Metabolism
Claes Lindh, Hemamali Samaratunga, Brett Delahunt, Rebecka Bergstrom, Venkatesh Chellappa, John Yaxley, Johan Lindberg, Lars Egevad
Summary: Most ductal and acinar prostate adenocarcinoma components of mixed tumors share the same clonal origin. Ductal adenocarcinoma components often exhibit genome doubling events leading to aneuploidy, consistent with the aggressive nature of high grade prostate cancer.
Article
Radiology, Nuclear Medicine & Medical Imaging
Matthew J. Roberts, Andrew Morton, Nathan Papa, Anthony Franklin, Sheliyan Raveenthiran, William J. Yaxley, Geoffrey Coughlin, Troy Gianduzzo, Boon Kua, Louise McEwan, David Wong, Brett Delahunt, Lars Egevad, Hemamali Samaratunga, Nicholas Brown, Robert Parkinson, Louise Emmett, John W. Yaxley
Summary: PSMA intensity on PSMA PET/CT is a clinically significant biomarker for predicting oncological outcomes and biochemical recurrence-free survival in patients undergoing radical prostatectomy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Editorial Material
Microbiology
Isabelle Chemin, Flor Helene Pujol
Letter
Pathology
Hemamal Samaratunga, Tony Gianduzzo, Joanna Perry-Keene, Lars Egevad, Brett Delahunt
Article
Cell Biology
Lars Egevad, Brett Delahunt, Kenneth A. Iczkowski, Theo van der Kwast, Geert J. L. H. van Leenders, Katia R. M. Leite, Chin-Chen Pan, Hemamali Samaratunga, Toyonori Tsuzuki, Nita Mulliqi, Xiaoyi Ji, Henrik Olsson, Masi Valkonen, Pekka Ruusuvuori, Martin Eklund, Kimmo Kartasalo
Summary: There is evidence that cribriform morphology is associated with a worse prognosis for prostatic adenocarcinoma. This study aimed to investigate the reproducibility of cribriform cancer diagnosis in prostate needle biopsies. A panel of nine prostate pathology experts independently reviewed 304 digitised biopsies and achieved a 2/3 consensus diagnosis of cribriform and noncribriform cancer in 90% of the cases. Strict diagnostic criteria were used to identify cribriform patterns and generate a set of consensus cases for standardization.
Article
Medicine, General & Internal
M. Alvaro Berbis, David S. McClintock, Andrey Bychkov, Jeroen Van der Laak, Liron Pantanowitz, Jochen K. Lennerz, Jerome Y. Cheng, Brett Delahunt, Lars Egevad, Catarina Eloy, Alton B. Farris III, Filippo Fraggetta, Raimundo Garcia del Moral, Douglas J. Hartman, Markus D. Herrmann, Eva Hollemans, Kenneth A. Iczkowski, Aly Karsan, Mark Kriegsmann, Mohamed E. Salama, John H. Sinard, J. Mark Tuthill, Bethany Williams, Cesar Casado-Sanchez, Victor Sanchez-Turrion, Antonio Luna, Jose Aneiros-Fernandez, Jeanne Shen
Summary: AI is expected to be routinely and impactfully used in pathology practice by 2030, according to experts in the field. This consensus study highlights the anticipated short-to-mid-term impact of AI and raises important practical, ethical, and legal challenges that need to be addressed prior to its clinical implementation.
Article
Oncology
Naveen S. Vasudev, Ghislaine Scelo, Kate I. Glennon, Michelle Wilson, Louis Letourneau, Robert Eveleigh, Nazanin Nourbehesht, Madeleine Arseneault, Antoine Paccard, Lars Egevad, Juris Viksna, Edgars Celms, Sharon M. Jackson, Behnoush Abedi-Ardekani, Anne Y. Warren, Peter J. Selby, Sebastian Trainor, Michael Kimuli, Jon Cartledge, Naeem Soomro, Adebanji Adeyoju, Poulam M. Patel, Magdalena B. Wozniak, Ivana Holcatova, Antonin Brisuda, Vladimir Janout, Estelle Chanudet, David Zaridze, Anush Moukeria, Oxana Shangina, Lenka Foretova, Marie Navratilova, Dana Mates, Viorel Jinga, Ljiljana Bogdanovic, Bozidar Kovacevic, Anne Cambon-Thomsen, Guillaume Bourque, Alvis Brazma, Jorg Tost, Paul Brennan, Mark Lathrop, Yasser Riazalhosseini, Rosamonde E. Banks
Summary: Targeted gene sequencing can help in risk prediction and adjuvant treatment decisions for patients with resected localized ccRCC. Mutations in the VHL gene have a significant impact on patient outcomes, independent of other gene mutations. Genomic characterization can personalize treatment discussions and inform future adjuvant trial design.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andres Felipe Cardona, Gonzalo Recondo
Summary: The landscape of targeted therapies for EGFR-mutant NSCLC is expanding, but resistance to treatment is a challenge. Understanding and using DNA sequencing has led to the development of innovative strategies to overcome or prevent resistance in the clinical setting.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Pathology
Murali Varma, Brett Delahunt, Liang Cheng, Runjan Chetty, Eva Comperat, Vikram Deshpande, Lars Egevad, Theodorus H. van der Kwast, Antonio Lopez-Beltran, W. Glenn McCluggage
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Angelos Heldin, Matko Cancer, Mireia Palomar-Siles, Susanne Ohlin, Meiqiongzi Zhang, Alexander Sun-Zhang, Anna Mariani, Jianping Liu, Vladimir J. N. Bykov, Klas G. G. Wiman
Summary: The TP53 and PTEN tumour suppressor genes are frequently inactivated by nonsense mutations in human tumours. In this study, two novel compounds were identified that can induce translational readthrough and restore the expression of full-length p53 protein in cells with TP53 nonsense mutations. Compound C47 showed synergy with G418, a known readthrough inducer, while compound C61 synergized with eRF3 degraders CC-885 and CC-90009. Furthermore, compound C47 also demonstrated potent induction of full-length PTEN protein in cells with different PTEN nonsense mutations. These findings may have implications for the development of targeted cancer therapy by pharmacologically inducing translational readthrough.
Letter
Pathology
Hemamali Samaratunga, Lars Egevad, Brett Delahunt
Review
Microbiology
Rayana Maryse Toye, Carmen Luisa Loureiro, Rossana Celeste Jaspe, Fabien Zoulim, Flor Helene Pujol, Isabelle Chemin
Summary: HBV genotypes E to J are understudied and have specific distributions across different regions. Genotype F is the most divergent and has further subgenotypes. There is a lack of data from sub-Saharan Africa and Latin America due to under-representation in clinical and research cohorts.
Review
Pathology
Murali Varma, Laura C. Collins, Runjan Chetty, Dipti M. Karamchandani, Karen Talia, John Dormer, Monika Vyas, Brendan Conn, Yaileen D. Guzman-Arocho, Adam Jones, Miranda Pring, W. Glenn Mccluggage
Summary: This paper highlights the importance of macroscopic examination and tissue sampling in histopathology reporting and discusses potential solutions and challenges. It emphasizes the need for adequate guidance and supervision in macroscopic examination and highlights the importance of clinical context, specimen fixation, macroscopic descriptions, and tissue sampling.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Cell Biology
Zhili Li, Claud Caron de Fromentel, Woojun Kim, Wen-Hung Wang, Jiazeng Sun, Bingyu Yan, Sagar Utturkar, Nadia Atallah Lanman, Bennett D. Elzey, Yoon Yeo, Hao Zhang, Majid Kazemian, Massimo Levrero, Ourania Andrisani
Summary: The expression of DDX5 is reduced in hepatocellular carcinoma (HCC) and is associated with higher tumor grade and poor patient survival after sorafenib treatment. The study shows that DDX5 downregulation by sorafenib mediates adaptive resistance by activating the Wnt/beta-catenin signaling pathway, leading to ferroptosis escape. Conversely, overexpression of DDX5 enhances the efficacy of sorafenib by suppressing Wnt/beta-catenin activation and induction of ferroptosis.
CELL DEATH & DISEASE
(2023)